Israel Englander Fate Therapeutics Inc Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Millennium Management LLC holds 50,000 shares of FATE stock, worth $81,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,000

Previous 446,668 88.81%

Holding current value

$81,000

Previous $1.47 Million 88.05%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $549,282 - $980,609	-176,052 Reduced 39.41%	270,616 $947,000
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $1.46 Million - $3.16 Million	446,668 New	446,668 $1.47 Million
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $443,168 - $1.06 Million	268,587 Added 42.97%	893,648 $3.34 Million
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $5.27 Million - $7.3 Million	-1,107,926 Reduced 63.93%	625,061 $2.98 Million
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $4.8 Million - $12.6 Million	-1,131,489 Reduced 39.5%	1,732,987 $9.88 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $21.9 Million - $53 Million	2,223,752 Added 347.07%	2,864,476 $28.9 Million
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $1.87 Million - $3.21 Million	-89,047 Reduced 12.2%	640,724 $14.4 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $7.46 Million - $17.8 Million	419,627 Added 135.3%	729,771 $18.1 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $8.6 Million - $17.5 Million	289,967 Added 1437.12%	310,144 $12 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $4.47 Million - $6.01 Million	-93,384 Reduced 82.23%	20,177 $1.18 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $3.2 Million - $5.17 Million	-53,973 Reduced 32.22%	113,561 $6.73 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $6.08 Million - $8.37 Million	-90,444 Reduced 35.06%	167,534 $14.5 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $3.75 Million - $6.1 Million	-51,973 Reduced 16.77%	257,978 $21.3 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $5.87 Million - $15.5 Million	-153,995 Reduced 33.19%	309,951 $28.2 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $20.6 Million - $27.4 Million	-676,289 Reduced 59.31%	463,946 $18.5 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $6.9 Million - $12 Million	341,200 Added 42.7%	1,140,235 $39.1 Million
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $13.4 Million - $24.7 Million	-776,073 Reduced 49.27%	799,035 $17.7 Million
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $23.8 Million - $36.9 Million	-1,780,011 Reduced 53.05%	1,575,108 $30.8 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $20.6 Million - $30 Million	1,332,134 Added 65.85%	3,355,119 $52.1 Million
Q2 2019 Aug 15, 2019	BUY	$15.61 - $20.44 $28.8 Million - $37.8 Million	1,847,580 Added 1053.32%	2,022,985 $41.1 Million
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $22.3 Million - $29.2 Million	-1,430,849 Reduced 89.08%	175,405 $167,000
Q1 2019 May 14, 2019	BUY	$13.15 - $18.71 $13.4 Million - $19.1 Million	1,018,614 Added 173.34%	1,606,254 $28.2 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $4.92 Million - $7.27 Million	428,399 Added 269.03%	587,640 $7.54 Million
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $4.6 Million - $8.57 Million	-525,901 Reduced 76.76%	159,241 $2.59 Million
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $6.28 Million - $9.24 Million	685,142 New	685,142 $7.77 Million
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $2.13 Million - $4.67 Million	-338,799 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $1.2 Million - $2.02 Million	303,999 Added 873.56%	338,799 $2.07 Million
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $90,480 - $149,988	34,800	34,800 $138,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $157M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account